Cord blood banking has been a new topic for the media and the public. Science has shown that the use of cord blood has many advantages and some drawbacks. One of these drawbacks is the cost of storing cord blood. If insurance companies were mandated to cover cord blood banking, then more people could benefit from cord blood banking. In the past, it was believed that cord blood was a waste product. It is now known that cord blood contains two types of stem cells that offer multiple treatment possibilities (Waller-Wise, 2011). Cord blood contains hematopoietic stem cells and pluripotent stem cells. Hematopoietic stem cells can be used for blood and immune system regeneration. Pluripotent stem cells have the ability to produce multiple tissue types of ectoderm, endoderm, and mesoderm (Einstein & Merkatz, 2008). Both types of stem cells show the ability to adapt to the treatment of a wide range of diseases, including neurological, cardiovascular, endocrine, orthopedic, and ophthalmic conditions (Einstein & Merkatz, 2008). Stem cells can be used through transplantation. Four major types of physical diseases that can be treated with stem cell transplants, including blood disorders, congenital metabolic disorders, immunodeficiencies, and some cancers (Waller-Wise, 2011). Some examples of diseases are sickle cell anemia, Tay-Sachs disease, Hodgkin's and non-Hodgkin's lymphoma, some leukemias, and many others (Waller-Wise, 2011). It is recommended that people with a family history of any of the known diseases that can be helped with stem cell transplant consider cord blood banking. Insurance companies will need to know that financing cord blood storage will have more benefits than risks. Treatment of these types of diseases is one of the advantages. Although this treatment is similar to bone marrow treatment, there are many more benefits to using cord blood. The only advantage is the ease of collecting cord blood. Furthermore, there is no risk to the mother or baby because it can be obtained from the placenta (Einstein & Merkatz, 2008). It takes less time to process, which means it's available sooner. There is less change in the development of graft-versus-host disease because it is much easier to find a match (Waller-Wise, 2011). Research into stem cell technology offers broad possibilities for future development. Emerging indications for the treatment of type 1 diabetes mellitus and some neurological lesions such as cerebral palsy are being researched.